Transgene Biotek to delist from Indian stock exchanges

Apart from Bombay Stock Exchange, the company is also listed on Luxembourg Stock Exchange

Biotechnology firm today said that its board of directors has decided to its shares from Indian stock exchanges.

"The board of directors of the company at its meeting held on September 3, 2012, inter alia, has decided to delist the equity shares of the company from the all the recognised Indian Stock Exchanges," Transgene Biotek said in a filing to BSE.

Apart from Bombay Stock Exchange, the company is also listed on Luxembourg Stock Exchange.

Transgene Biotek said its proposal to delist is subject to approval of shareholders of the company and statutory approvals.

The company, however, did not assign any reason for the delisting.

Shares of Transgene Biotek were today trading at Rs 11.25 per scrip in the afternoon trade on BSE, up 4.85% from its previous close.

 Founded in 1991 by Koteswara Rao, the Hyderabad-based company is among the first biotechnology in India.

It has products in the therapeutic areas of cancer, auto immunity and other bio-generics apart from drug delivery devices for ailments such as diabetes and HIV infection.

image
Business Standard
177 22
Business Standard

Transgene Biotek to delist from Indian stock exchanges

Apart from Bombay Stock Exchange, the company is also listed on Luxembourg Stock Exchange

Press Trust of India  |  New Delhi 



Biotechnology firm today said that its board of directors has decided to its shares from Indian stock exchanges.

"The board of directors of the company at its meeting held on September 3, 2012, inter alia, has decided to delist the equity shares of the company from the all the recognised Indian Stock Exchanges," Transgene Biotek said in a filing to BSE.

Apart from Bombay Stock Exchange, the company is also listed on Luxembourg Stock Exchange.

Transgene Biotek said its proposal to delist is subject to approval of shareholders of the company and statutory approvals.



The company, however, did not assign any reason for the delisting.

Shares of Transgene Biotek were today trading at Rs 11.25 per scrip in the afternoon trade on BSE, up 4.85% from its previous close.

 Founded in 1991 by Koteswara Rao, the Hyderabad-based company is among the first biotechnology in India.

It has products in the therapeutic areas of cancer, auto immunity and other bio-generics apart from drug delivery devices for ailments such as diabetes and HIV infection.

RECOMMENDED FOR YOU

Transgene Biotek to delist from Indian stock exchanges

Apart from Bombay Stock Exchange, the company is also listed on Luxembourg Stock Exchange

Biotechnology firm Transgene Biotek today said that its board of directors has decided to delist its shares from Indian stock exchanges.

Biotechnology firm today said that its board of directors has decided to its shares from Indian stock exchanges.

"The board of directors of the company at its meeting held on September 3, 2012, inter alia, has decided to delist the equity shares of the company from the all the recognised Indian Stock Exchanges," Transgene Biotek said in a filing to BSE.

Apart from Bombay Stock Exchange, the company is also listed on Luxembourg Stock Exchange.

Transgene Biotek said its proposal to delist is subject to approval of shareholders of the company and statutory approvals.

The company, however, did not assign any reason for the delisting.

Shares of Transgene Biotek were today trading at Rs 11.25 per scrip in the afternoon trade on BSE, up 4.85% from its previous close.

 Founded in 1991 by Koteswara Rao, the Hyderabad-based company is among the first biotechnology in India.

It has products in the therapeutic areas of cancer, auto immunity and other bio-generics apart from drug delivery devices for ailments such as diabetes and HIV infection.

image
Business Standard
177 22
Widgets Magazine

More News

Widgets Magazine
Widgets Magazine

Upgrade To Premium Services

Welcome User

Business Standard is happy to inform you of the launch of "Business Standard Premium Services"

As a premium subscriber you get an across device unfettered access to a range of services which include:

  • Access Exclusive content - articles, features & opinion pieces
  • Weekly Industry/Genre specific newsletters - Choose multiple industries/genres
  • Access to 17 plus years of content archives
  • Set Stock price alerts for your portfolio and watch list and get them delivered to your e-mail box
  • End of day news alerts on 5 companies (via email)
  • NEW: Get seamless access to WSJ.com at a great price. No additional sign-up required.
 

Premium Services

In Partnership with

 

Dear Guest,

 

Welcome to the premium services of Business Standard brought to you courtesy FIS.
Kindly visit the Manage my subscription page to discover the benefits of this programme.

Enjoy Reading!
Team Business Standard